Baxter Issues Recall Due to Particulate Matter - - BioPharm International

ADVERTISEMENT

Baxter Issues Recall Due to Particulate Matter


Baxter Healthcare Corp. has initiated a nationwide recall of more than 20,000 containers of Brevibloc Premixed Injection, esmolol hydrochloride in sodium chloride due to the presence of particulate matter.

According to FDA’s July 9 enforcement report, Baxter received complaints of discolored solution identified as subvisible particles of iron oxide that are agglomerating. Baxter issued the recall voluntarily on June 16, 2014.

The recall involved 2,500 mg/250 mL (10 mg/mL), 250 mL Single Use IntraVia container, packaged in 10 x 250 mL Single Use IntraVia containers per carton.

Source: FDA

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
FDA and NIH Win Award for IP Licensing of Meningitis Vaccine
September 26, 2014
FDA Releases REMS Report
September 25, 2014
Author Guidelines

Click here